Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cancerimmunterapi til behandling af hæmatologisk cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. FDG PET/CT in cancer: comparison of actual use with literature-based recommendations

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Maja Bech Juul
  • Pernille Hammershoej Jensen
  • Henriette Engberg
  • Sonja Wehberg
  • Andriette Dessau-Arp
  • Donika Haziri
  • Helene Bjoerg Kristensen
  • Joachim Baech
  • Lene Schurmann
  • Michael Roost Clausen
  • Rebecca Valentin
  • Lene Meldgaard Knudsen
  • Lars Munksgaard
  • Tarec Christoffer El-Galaly
  • Henrik Frederiksen
  • Thomas Stauffer Larsen
View graph of relations

BACKGROUND: Optimal treatment strategy for the oldest patients with diffuse large B-cell lymphoma (DLBCL) remains controversial, as this group often is precluded from clinical trials, and population-based studies are limited.

METHODS: All Danish DLBCL-patients ≥75 years diagnosed from 2003 to 2012 were identified, using the Danish National Lymphoma Registry (LYFO). Information regarding baseline characteristics, treatment, comorbidities and outcomes was retrieved from LYFO, the Danish National health registries and medical records. Patients were stratified by age (75-79; 80-84 and 85 + years), comorbidity score and treatment modality (standard treatment [R-CHOP/CHOP-like], less intensive regimens or palliative treatment).

FINDINGS: A total of 1011 patients were included. Standard treatment was initiated in 64%, ranging from 83% among patients aged 75-79 years to 32% among patient aged 85 + years. With standard treatment, median overall survival (OS) estimates were 4·6, 2·6, and 1·9 years for the age groups 75-79, 80-84 and 85+ years. Among patient aged 75-79 and 80-84 years, OS was superior with standard treatment, although high comorbidity scores attenuated this association. Among patients aged 85+ years, survival was not influenced by treatment intensity. Patients ≥80 years had similar OS regardless of intended (R-)CHOP dosing, whereas patients of 75-79 years scheduled for full dose had higher OS. Standard treatment was not associated with increased hospitalisation.

INTERPRETATION: Standard treatment is feasible with good outcomes in a large proportion of elderly DLBCL-patients. Planned dose reduction in patients aged ≥80 years had no negative impact on OS.

Original languageEnglish
JournalEuropean journal of cancer (Oxford, England : 1990)
Volume99
Pages (from-to)86-96
Number of pages11
ISSN0959-8049
DOIs
Publication statusPublished - Aug 2018

ID: 56690673